Breakthrough in Precision Oncology: Next-Generation mRNA Vaccines Enter Phase 3 Trials
Personalized neoantigen immunotherapies combined with checkpoint inhibitors demonstrate unprecedented progression-free survival rates in clinical multi-center evaluations.
Dr. Priya Patel6 days ago